These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 1687043

  • 1. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.
    Martino E, Balzano S, Bartalena L, Loviselli A, Sica V, Petrini L, Grasso L, Piga M, Braverman LE.
    J Endocrinol Invest; 1991 Nov; 14(10):847-51. PubMed ID: 1687043
    [Abstract] [Full Text] [Related]

  • 2. Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves' disease.
    Roti E, Gardini E, Minelli R, Bianconi L, Braverman LE.
    Metabolism; 1993 Apr; 42(4):403-8. PubMed ID: 8487661
    [Abstract] [Full Text] [Related]

  • 3. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M, Koizumi Y, Aizawa T, Yamada T, Takahashi Y, Watanabe T, Kamoi K.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [Abstract] [Full Text] [Related]

  • 4. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
    Werner RS, Romaldini JH, Farah CS, Werner MC, Bromberg N.
    Thyroid; 1991 Jan; 1(4):293-9. PubMed ID: 1688155
    [Abstract] [Full Text] [Related]

  • 5. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T, Koizumi Y, Sato A, Hashizume K, Aizawa T, Takasu N, Nagata H.
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [Abstract] [Full Text] [Related]

  • 6. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A, Yamada T, Aizawa T, Ichikawa K, Komiya I, Takasu N, Takemura Y.
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [Abstract] [Full Text] [Related]

  • 7. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T.
    N Engl J Med; 1991 Apr 04; 324(14):947-53. PubMed ID: 1900575
    [Abstract] [Full Text] [Related]

  • 8. Long term treatment of Graves' hyperthyroidism with sodium ipodate.
    Shen DC, Wu SY, Chopra IJ, Huang HW, Shian LR, Bian TY, Jeng CY, Solomon DH.
    J Clin Endocrinol Metab; 1985 Oct 04; 61(4):723-7. PubMed ID: 3928675
    [Abstract] [Full Text] [Related]

  • 9. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease.
    Roti E, Robuschi G, Gardini E, Montermini M, Salvi M, Manfredi A, Gnudi A, Braverman LE.
    Clin Endocrinol (Oxf); 1988 Mar 04; 28(3):305-14. PubMed ID: 3168311
    [Abstract] [Full Text] [Related]

  • 10. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE.
    J Clin Endocrinol Metab; 1993 Apr 04; 76(4):928-32. PubMed ID: 7682562
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E.
    Thyroid; 2006 Mar 04; 16(3):295-302. PubMed ID: 16571093
    [Abstract] [Full Text] [Related]

  • 13. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, Kumagai LF, Nagataki S.
    J Clin Endocrinol Metab; 1995 May 04; 80(5):1481-4. PubMed ID: 7744989
    [Abstract] [Full Text] [Related]

  • 14. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK, Yoo WS, Kim DW, Chung HK.
    Thyroid; 2010 Sep 04; 20(9):949-54. PubMed ID: 20629556
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate.
    Karpman BA, Rapoport B, Filetti S, Fisher DA.
    J Clin Endocrinol Metab; 1987 Jan 04; 64(1):119-23. PubMed ID: 3782427
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N, Yoshida K, Mori K, Kiso Y, Sayama N, Tani JI, Nakagawa Y, Ito S.
    Thyroid; 1999 Aug 04; 9(8):775-9. PubMed ID: 10482369
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.